Postoperative radiotherapy for T1/2N0M0 mucoepidermoid carcinoma positive for CRTC1/3‐MAML2 fusions
Background The National Comprehensive Cancer Network (NCCN) guidelines recommend considering postoperative radiotherapy (PORT) for completely resected T1/2N0M0 salivary mucoepidermoid carcinomas when they show tumor spillage, perineural invasion, or intermediate/high‐grade histology. CRTC1/3‐MAML2 f...
Gespeichert in:
| Veröffentlicht in: | Head & neck 2018-12, Vol.40 (12), p.2565-2573 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2573 |
|---|---|
| container_issue | 12 |
| container_start_page | 2565 |
| container_title | Head & neck |
| container_volume | 40 |
| creator | Okumura, Yoshihide Murase, Takayuki Saida, Kosuke Fujii, Kana Takino, Hisashi Masaki, Ayako Ijichi, Kei Shimozato, Kazuo Tada, Yuichiro Nibu, Ken‐ichi Inagaki, Hiroshi |
| description | Background
The National Comprehensive Cancer Network (NCCN) guidelines recommend considering postoperative radiotherapy (PORT) for completely resected T1/2N0M0 salivary mucoepidermoid carcinomas when they show tumor spillage, perineural invasion, or intermediate/high‐grade histology. CRTC1/3‐MAML2 fusions have been associated with a favorable clinical outcome.
Methods
Forty‐seven T1/2N0M0 mucoepidermoid carcinoma cases positive for CRTC1/3‐MAML2 fusions were completely resected and were not treated with PORT.
Results
Pathologically, none of the cases showed tumor spillage or perineural invasion. Cases with intermediate/high‐grade histology numbered 9 (19%) to 26 (55%) with the currently used 3 different grading systems. During the follow‐up (median 60 months), locoregional tumor recurrence occurred in 4 cases, which were treated with surgery alone. At the last follow‐up (median 60 months; 7‐160), all patients were alive with no evidence of disease.
Conclusion
An excellent prognosis may be achieved without PORT in T1/2N0M0 mucoepidermoid carcinoma patients positive for CRTC1/3‐MAML2 fusions when the tumors are completely resected without tumor spillage. |
| doi_str_mv | 10.1002/hed.24856 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2138050806</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2138050806</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4196-69b362bc9ac8378e95dbea756fc5cf58d3c9c3d2056b01636864babadb91797a3</originalsourceid><addsrcrecordid>eNp10MtKw0AUBuBBFO8LX0ACbnSR9sw9WUqtVmhVpK7DZDLBkaYTZxqlOx_BZ_RJnFq7EVzNhe_8HH6ETjD0MADpP5uqR1jGxRbax5DLFCiT26s7oykFyfbQQQgvAEAFI7tojwKTnIHcR-bBhYVrjVcL-2YSryrrFs_x2S6T2vlkivvkDiaQNJ12prWV8Y2zVaKV13buGpW0Ltif2RUfPE4HuE-_Pj4nl5MxSeouWDcPR2inVrNgjn_PQ_R0PZwORun4_uZ2cDlONcO5SEVeUkFKnSudUZmZnFelUZKLWnNd86yiOte0IsBFCVhQkQlWqlJVZY5lLhU9ROfr3Na7186ERdHYoM1spubGdaEgmGbAIQMR6dkf-uI6P4_bRSUwoUwwHtXFWmnvQvCmLlpvG-WXBYZi1X0Ruy9-uo_29DexK5v4u5GbsiPor8G7nZnl_0nFaHi1jvwGQuOM7w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2161234645</pqid></control><display><type>article</type><title>Postoperative radiotherapy for T1/2N0M0 mucoepidermoid carcinoma positive for CRTC1/3‐MAML2 fusions</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Okumura, Yoshihide ; Murase, Takayuki ; Saida, Kosuke ; Fujii, Kana ; Takino, Hisashi ; Masaki, Ayako ; Ijichi, Kei ; Shimozato, Kazuo ; Tada, Yuichiro ; Nibu, Ken‐ichi ; Inagaki, Hiroshi</creator><creatorcontrib>Okumura, Yoshihide ; Murase, Takayuki ; Saida, Kosuke ; Fujii, Kana ; Takino, Hisashi ; Masaki, Ayako ; Ijichi, Kei ; Shimozato, Kazuo ; Tada, Yuichiro ; Nibu, Ken‐ichi ; Inagaki, Hiroshi</creatorcontrib><description>Background
The National Comprehensive Cancer Network (NCCN) guidelines recommend considering postoperative radiotherapy (PORT) for completely resected T1/2N0M0 salivary mucoepidermoid carcinomas when they show tumor spillage, perineural invasion, or intermediate/high‐grade histology. CRTC1/3‐MAML2 fusions have been associated with a favorable clinical outcome.
Methods
Forty‐seven T1/2N0M0 mucoepidermoid carcinoma cases positive for CRTC1/3‐MAML2 fusions were completely resected and were not treated with PORT.
Results
Pathologically, none of the cases showed tumor spillage or perineural invasion. Cases with intermediate/high‐grade histology numbered 9 (19%) to 26 (55%) with the currently used 3 different grading systems. During the follow‐up (median 60 months), locoregional tumor recurrence occurred in 4 cases, which were treated with surgery alone. At the last follow‐up (median 60 months; 7‐160), all patients were alive with no evidence of disease.
Conclusion
An excellent prognosis may be achieved without PORT in T1/2N0M0 mucoepidermoid carcinoma patients positive for CRTC1/3‐MAML2 fusions when the tumors are completely resected without tumor spillage.</description><identifier>ISSN: 1043-3074</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.24856</identifier><identifier>PMID: 30475407</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Carcinoma ; Carcinoma, Mucoepidermoid - pathology ; Carcinoma, Mucoepidermoid - radiotherapy ; Carcinoma, Mucoepidermoid - surgery ; CRTC1/3‐MAML2 ; Disease-Free Survival ; DNA, Neoplasm - analysis ; Female ; Follow-Up Studies ; Gene Fusion ; Head and neck ; Histology ; Humans ; Male ; Middle Aged ; mucoepidermoid carcinoma ; National Comprehensive Cancer Network (NCCN) guidelines ; postoperative radiotherapy ; Prognosis ; Radiation therapy ; Radiotherapy, Adjuvant ; Retrospective Studies ; Salivary Gland Neoplasms - pathology ; Salivary Gland Neoplasms - radiotherapy ; Salivary Gland Neoplasms - surgery ; Sequence Analysis, DNA ; Surgery ; T1/2N0M0 ; Trans-Activators - genetics ; Transcription Factors - genetics ; Tumors ; Young Adult</subject><ispartof>Head & neck, 2018-12, Vol.40 (12), p.2565-2573</ispartof><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4196-69b362bc9ac8378e95dbea756fc5cf58d3c9c3d2056b01636864babadb91797a3</citedby><cites>FETCH-LOGICAL-c4196-69b362bc9ac8378e95dbea756fc5cf58d3c9c3d2056b01636864babadb91797a3</cites><orcidid>0000-0001-6157-636X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhed.24856$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhed.24856$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30475407$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Okumura, Yoshihide</creatorcontrib><creatorcontrib>Murase, Takayuki</creatorcontrib><creatorcontrib>Saida, Kosuke</creatorcontrib><creatorcontrib>Fujii, Kana</creatorcontrib><creatorcontrib>Takino, Hisashi</creatorcontrib><creatorcontrib>Masaki, Ayako</creatorcontrib><creatorcontrib>Ijichi, Kei</creatorcontrib><creatorcontrib>Shimozato, Kazuo</creatorcontrib><creatorcontrib>Tada, Yuichiro</creatorcontrib><creatorcontrib>Nibu, Ken‐ichi</creatorcontrib><creatorcontrib>Inagaki, Hiroshi</creatorcontrib><title>Postoperative radiotherapy for T1/2N0M0 mucoepidermoid carcinoma positive for CRTC1/3‐MAML2 fusions</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
The National Comprehensive Cancer Network (NCCN) guidelines recommend considering postoperative radiotherapy (PORT) for completely resected T1/2N0M0 salivary mucoepidermoid carcinomas when they show tumor spillage, perineural invasion, or intermediate/high‐grade histology. CRTC1/3‐MAML2 fusions have been associated with a favorable clinical outcome.
Methods
Forty‐seven T1/2N0M0 mucoepidermoid carcinoma cases positive for CRTC1/3‐MAML2 fusions were completely resected and were not treated with PORT.
Results
Pathologically, none of the cases showed tumor spillage or perineural invasion. Cases with intermediate/high‐grade histology numbered 9 (19%) to 26 (55%) with the currently used 3 different grading systems. During the follow‐up (median 60 months), locoregional tumor recurrence occurred in 4 cases, which were treated with surgery alone. At the last follow‐up (median 60 months; 7‐160), all patients were alive with no evidence of disease.
Conclusion
An excellent prognosis may be achieved without PORT in T1/2N0M0 mucoepidermoid carcinoma patients positive for CRTC1/3‐MAML2 fusions when the tumors are completely resected without tumor spillage.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Carcinoma</subject><subject>Carcinoma, Mucoepidermoid - pathology</subject><subject>Carcinoma, Mucoepidermoid - radiotherapy</subject><subject>Carcinoma, Mucoepidermoid - surgery</subject><subject>CRTC1/3‐MAML2</subject><subject>Disease-Free Survival</subject><subject>DNA, Neoplasm - analysis</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gene Fusion</subject><subject>Head and neck</subject><subject>Histology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>mucoepidermoid carcinoma</subject><subject>National Comprehensive Cancer Network (NCCN) guidelines</subject><subject>postoperative radiotherapy</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Radiotherapy, Adjuvant</subject><subject>Retrospective Studies</subject><subject>Salivary Gland Neoplasms - pathology</subject><subject>Salivary Gland Neoplasms - radiotherapy</subject><subject>Salivary Gland Neoplasms - surgery</subject><subject>Sequence Analysis, DNA</subject><subject>Surgery</subject><subject>T1/2N0M0</subject><subject>Trans-Activators - genetics</subject><subject>Transcription Factors - genetics</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>1043-3074</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10MtKw0AUBuBBFO8LX0ACbnSR9sw9WUqtVmhVpK7DZDLBkaYTZxqlOx_BZ_RJnFq7EVzNhe_8HH6ETjD0MADpP5uqR1jGxRbax5DLFCiT26s7oykFyfbQQQgvAEAFI7tojwKTnIHcR-bBhYVrjVcL-2YSryrrFs_x2S6T2vlkivvkDiaQNJ12prWV8Y2zVaKV13buGpW0Ltif2RUfPE4HuE-_Pj4nl5MxSeouWDcPR2inVrNgjn_PQ_R0PZwORun4_uZ2cDlONcO5SEVeUkFKnSudUZmZnFelUZKLWnNd86yiOte0IsBFCVhQkQlWqlJVZY5lLhU9ROfr3Na7186ERdHYoM1spubGdaEgmGbAIQMR6dkf-uI6P4_bRSUwoUwwHtXFWmnvQvCmLlpvG-WXBYZi1X0Ruy9-uo_29DexK5v4u5GbsiPor8G7nZnl_0nFaHi1jvwGQuOM7w</recordid><startdate>201812</startdate><enddate>201812</enddate><creator>Okumura, Yoshihide</creator><creator>Murase, Takayuki</creator><creator>Saida, Kosuke</creator><creator>Fujii, Kana</creator><creator>Takino, Hisashi</creator><creator>Masaki, Ayako</creator><creator>Ijichi, Kei</creator><creator>Shimozato, Kazuo</creator><creator>Tada, Yuichiro</creator><creator>Nibu, Ken‐ichi</creator><creator>Inagaki, Hiroshi</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6157-636X</orcidid></search><sort><creationdate>201812</creationdate><title>Postoperative radiotherapy for T1/2N0M0 mucoepidermoid carcinoma positive for CRTC1/3‐MAML2 fusions</title><author>Okumura, Yoshihide ; Murase, Takayuki ; Saida, Kosuke ; Fujii, Kana ; Takino, Hisashi ; Masaki, Ayako ; Ijichi, Kei ; Shimozato, Kazuo ; Tada, Yuichiro ; Nibu, Ken‐ichi ; Inagaki, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4196-69b362bc9ac8378e95dbea756fc5cf58d3c9c3d2056b01636864babadb91797a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Carcinoma</topic><topic>Carcinoma, Mucoepidermoid - pathology</topic><topic>Carcinoma, Mucoepidermoid - radiotherapy</topic><topic>Carcinoma, Mucoepidermoid - surgery</topic><topic>CRTC1/3‐MAML2</topic><topic>Disease-Free Survival</topic><topic>DNA, Neoplasm - analysis</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gene Fusion</topic><topic>Head and neck</topic><topic>Histology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>mucoepidermoid carcinoma</topic><topic>National Comprehensive Cancer Network (NCCN) guidelines</topic><topic>postoperative radiotherapy</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Radiotherapy, Adjuvant</topic><topic>Retrospective Studies</topic><topic>Salivary Gland Neoplasms - pathology</topic><topic>Salivary Gland Neoplasms - radiotherapy</topic><topic>Salivary Gland Neoplasms - surgery</topic><topic>Sequence Analysis, DNA</topic><topic>Surgery</topic><topic>T1/2N0M0</topic><topic>Trans-Activators - genetics</topic><topic>Transcription Factors - genetics</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okumura, Yoshihide</creatorcontrib><creatorcontrib>Murase, Takayuki</creatorcontrib><creatorcontrib>Saida, Kosuke</creatorcontrib><creatorcontrib>Fujii, Kana</creatorcontrib><creatorcontrib>Takino, Hisashi</creatorcontrib><creatorcontrib>Masaki, Ayako</creatorcontrib><creatorcontrib>Ijichi, Kei</creatorcontrib><creatorcontrib>Shimozato, Kazuo</creatorcontrib><creatorcontrib>Tada, Yuichiro</creatorcontrib><creatorcontrib>Nibu, Ken‐ichi</creatorcontrib><creatorcontrib>Inagaki, Hiroshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okumura, Yoshihide</au><au>Murase, Takayuki</au><au>Saida, Kosuke</au><au>Fujii, Kana</au><au>Takino, Hisashi</au><au>Masaki, Ayako</au><au>Ijichi, Kei</au><au>Shimozato, Kazuo</au><au>Tada, Yuichiro</au><au>Nibu, Ken‐ichi</au><au>Inagaki, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Postoperative radiotherapy for T1/2N0M0 mucoepidermoid carcinoma positive for CRTC1/3‐MAML2 fusions</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2018-12</date><risdate>2018</risdate><volume>40</volume><issue>12</issue><spage>2565</spage><epage>2573</epage><pages>2565-2573</pages><issn>1043-3074</issn><eissn>1097-0347</eissn><abstract>Background
The National Comprehensive Cancer Network (NCCN) guidelines recommend considering postoperative radiotherapy (PORT) for completely resected T1/2N0M0 salivary mucoepidermoid carcinomas when they show tumor spillage, perineural invasion, or intermediate/high‐grade histology. CRTC1/3‐MAML2 fusions have been associated with a favorable clinical outcome.
Methods
Forty‐seven T1/2N0M0 mucoepidermoid carcinoma cases positive for CRTC1/3‐MAML2 fusions were completely resected and were not treated with PORT.
Results
Pathologically, none of the cases showed tumor spillage or perineural invasion. Cases with intermediate/high‐grade histology numbered 9 (19%) to 26 (55%) with the currently used 3 different grading systems. During the follow‐up (median 60 months), locoregional tumor recurrence occurred in 4 cases, which were treated with surgery alone. At the last follow‐up (median 60 months; 7‐160), all patients were alive with no evidence of disease.
Conclusion
An excellent prognosis may be achieved without PORT in T1/2N0M0 mucoepidermoid carcinoma patients positive for CRTC1/3‐MAML2 fusions when the tumors are completely resected without tumor spillage.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30475407</pmid><doi>10.1002/hed.24856</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6157-636X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2018-12, Vol.40 (12), p.2565-2573 |
| issn | 1043-3074 1097-0347 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2138050806 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Aged Aged, 80 and over Carcinoma Carcinoma, Mucoepidermoid - pathology Carcinoma, Mucoepidermoid - radiotherapy Carcinoma, Mucoepidermoid - surgery CRTC1/3‐MAML2 Disease-Free Survival DNA, Neoplasm - analysis Female Follow-Up Studies Gene Fusion Head and neck Histology Humans Male Middle Aged mucoepidermoid carcinoma National Comprehensive Cancer Network (NCCN) guidelines postoperative radiotherapy Prognosis Radiation therapy Radiotherapy, Adjuvant Retrospective Studies Salivary Gland Neoplasms - pathology Salivary Gland Neoplasms - radiotherapy Salivary Gland Neoplasms - surgery Sequence Analysis, DNA Surgery T1/2N0M0 Trans-Activators - genetics Transcription Factors - genetics Tumors Young Adult |
| title | Postoperative radiotherapy for T1/2N0M0 mucoepidermoid carcinoma positive for CRTC1/3‐MAML2 fusions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T01%3A23%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Postoperative%20radiotherapy%20for%20T1/2N0M0%20mucoepidermoid%20carcinoma%20positive%20for%20CRTC1/3%E2%80%90MAML2%20fusions&rft.jtitle=Head%20&%20neck&rft.au=Okumura,%20Yoshihide&rft.date=2018-12&rft.volume=40&rft.issue=12&rft.spage=2565&rft.epage=2573&rft.pages=2565-2573&rft.issn=1043-3074&rft.eissn=1097-0347&rft_id=info:doi/10.1002/hed.24856&rft_dat=%3Cproquest_cross%3E2138050806%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2161234645&rft_id=info:pmid/30475407&rfr_iscdi=true |